Microbiome Investors

4BIO Capital is a London-based venture capital firm specializing in life sciences investments. The firm focuses on advanced therapies that address significant unmet medical and social needs. Their investment strategy encompasses various therapeutic areas, including gene therapy, cell therapy, RNA-based therapy, targeted therapies, and microbiome-based treatments.

Seventure Partners is a leading European venture capital firm established in 1997, specializing in high-growth potential businesses within the fields of Life Sciences and Digital Technologies. With €950 million in net commitments under management as of the end of 2022, the firm has a strong presence in Europe, Israel, Asia, and North America. Seventure Partners focuses on innovative companies that generate positive impacts on society, sustainability, and the planet. In Life Sciences, the firm invests in sectors such as Microbiome, Nutrition, Foodtech, Medtech, Connected Health, Digital Health, Biotech, Pharmaceuticals, Industrial Biotech, Cleantech, Animal Health, and Agriculture. In Digital Technologies, the focus areas include Fintech, Retailtech, and other innovative digital solutions.

Thrive by SVG Ventures is a venture capital firm specializing in pre seed, seed, series A early-stage and later-stage investments. It prefers to invest in agriculture, food & climate technology, regenerative agriculture, soil health, biodiversity & ecosystem restoration, climate resilience & adaptation, sustainable farming practices, novel fertilizers & application, nutrient use efficiency tracking, artificial intelligence & automation, AI-powered farm management platforms, robotics and automation, AI-driven crop health diagnostics, supply chain optimization, data-driven decision making, vertical and urban farming technologies, animal health & nutrition, precision nutrition, disease prevention and management, sustainability in livestock systems, animal welfare and behavior monitoring, genetic and breeding innovations, clean energy & climate tech, renewable energy in agriculture, energy storage and grid solutions for farms, electrification of agricultural equipment, carbon capture and climate-smart agriculture, biofuels & green inputs for agriculture, energy efficiency in ammonia & nitrogen fertilizer production, water & waste management, water conservation & efficient irrigation, waste reduction & recycling in agriculture, nutrient runoff & water pollution control, circular water systems & reuse, organic waste conversion & bioenergy production, post-harvest & foodtech, future crops & novel ingredients, lab-grown & plant-based meats, sustainable packaging & food preservation, AI-driven & advanced processing tech, supply chain & food quality solutions for post-harvest, innovative plant breeding, pest management, resource-efficient technologies, sustainable crop production, biotech, life sciences, crop biologicals, crop protection, crop genomics & gene editing, biotech tools, synbio platforms, food & nutrition, microbiome, alternative protein, performance/healthy foods, aquaculture, supply chain, traceability & transparency resilience, novel equipment, harvest, transport & storage, digital farming, robotics & AI, indoor farming, predictive analytics, data platforms, farm & resource management, health & nutrition, next generation supply chain, novel food & beverage, novel ingredients, novel packaging, quality and shelf life, and robotics & automation. It prefers to invest in Alberta, Canada, U.S. and North America. Thrive by SVG Ventures was founded in 2014 and is based in Los Gatos, California with additional offices in Dublin, Ireland, Calgary, Canada and Melbourne, Australia.

MP Healthcare Venture Management, Inc. is a jointly owned venture capital arm of Mitsubishi Tanabe Pharma Corp. and Mitsubishi Chemical Holdings Corporation, specializing in seed, startups and early investments. The firm considers investing in life science companies with a focus on biotechnology, therapeutics, platform technologies, diagnostics and vaccines. It prefers to invest in novel drugs and diagnostics in various rare disease areas, neurodegeneration, nephrology, biochemistry, infectious disease, immunology and inflammation, cardiovascular, neuroscience, strokes, metabolic diseases and neurodegenerative disorders. In platform technologies it prefers to invest in regenerative medicine, synthetic biology, microbiome, gene therapy and nucleic acid medicine. The firm typically invests in North America and Europe. It usually invests as part of an investment syndicate with other leading venture capital firms. MP Healthcare Venture Management, Inc. was founded in 2006 and is based in Cambridge, Massachusetts with additional offices in Boston, Massachusetts.